Mangoceuticals, Inc. announced on September 30, 2026, that its subsidiary MangoRx IP Holdings secured a $2.5 million strategic investment for a 25% ownership stake in the entity holding the patent portfolio for MGX-0024 antiviral technology. Two accredited investors contributed an initial tranche of $1.75 million, receiving 18.9% (17.5% post-transaction) of MangoRx IP, with a final payment of $750,000 due by November 28, 2026, for the remaining 7.5%. The transaction was structured at the subsidiary level to avoid diluting Mangoceuticals' public common stock. This capital supports commercialization efforts for oral-care and livestock applications under brands like MangoRx and PeachesRx in the telemedicine and health products industry.
